SRC and cancer: Since Y32/Y64 are well conserved in human Ras proteins [35], targeting Src-phosphorylated Ras itself as well as its complexes with regulator and effector proteins is an appealing strategy to develop specific Ras inhibitors to treat Ras-driven cancers.